Atomic AI

Atomic AI specializes in AI-driven RNA drug discovery with atomic precision. The company leverages a proprietary platform that uses deep learning foundation models to develop RNA-targeted small molecules, RNA-based medicines, and RNA tools. Atomic AI aims to engineer RNA biology through artificial intelligence to create treatments for previously untreatable diseases. The company raised $35 million in Series A financing to advance its AI-driven RNA Structure Platform, targeting undruggable diseases. Atomic AI created the first large language model using chemical mapping data to optimize RNA therapeutic development. The company’s technology was featured on the cover of Science in the article ‘Geometric deep learning of RNA structure.’ Additionally, Atomic AI developed the Platform for AI-driven RNA Structure Exploration (PARSE) to generate RNA structural datasets and predict RNA motifs. The company offers a comprehensive employee benefits package, including 100% paid medical coverage, flexible time off, and a hybrid work environment.